Evidence map›Paper›PMID 39881564›Full record

ArticlemAbs2025

Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study.

Jennifer Moore, Alicia Aylott, Wen-Hung Chen, Jerzy Daniluk, Ian A Hawes, Sergio Parra, Prosenjit Sarkar, Yasmin Sanchez-Pearson, Megan Turner, Amanda Peppercorn and 1 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05280717 (A Phase 1, Open-label, Randomized, Parallel Group, Single-dose Clinical Pharmacology Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Different Concentrations of Sotrovimab Administered at Different Injection Sites, in Male or Female Healthy Participants Aged 18 to 65 Years), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05280717 phase1terminatednot on this map

A Phase 1, Open-label, Randomized, Parallel Group, Single-dose Clinical Pharmacology Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Different Concentrations of Sotrovimab Administered at Different Injection Sites, in Male or Female Healthy Participants Aged 18 to 65 Years

TypeinterventionalSponsorVir Biotechnology, Inc.Ran2022 to 2023Enrolled316ConditionsCovid19Armssotrovimab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer MooreGSK, Brentford, UK.
Alicia AylottGSK, Stevenage, UK.
Wen-Hung ChenGSK, Collegeville, PA, USA.ORCID 0000-0002-6610-9709
Jerzy DanilukGSK, Warsaw, Poland.
Ian A HawesGSK, Mississauga, ON, Canada.ORCID 0000-0003-3628-4087
Sergio ParraVir Biotechnology, Inc., San Francisco, CA, USA.ORCID 0000-0002-3191-0475
Prosenjit SarkarGSK, Bengaluru, India.
Yasmin Sanchez-PearsonGSK, Brentford, UK.ORCID 0009-0007-6216-6291
Megan TurnerGSK, Collegeville, PA, USA.ORCID 0000-0002-8624-8108
Amanda PeppercornGSK, Cambridge, MA, USA.ORCID 0000-0002-9162-2539
Andrew SkingsleyGSK, Brentford, UK.ORCID 0000-0003-4826-4585

Funding

GSK STUDY 218128
6 · The paper itself

Abstract

trial registrationClinicalTrials.gov identifier, NCT05280717.

Indexed as

Antibodies, Monoclonal, HumanizedAdultAgedFemaleHumansInjections, IntramuscularMaleMiddle AgedAntibodies, Monoclonal, HumanizedCOVID-19injection-site reactionintramuscularmonoclonal antibodypainpatient-reported outcomePhase 1safetysotrovimabtolerability

Identifiers

PMID39881564
PMCPMC11784644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.